LXRX | Ticker Profile - Titan Protect

LXRX

Lexicon Pharmaceuticals, Inc.

Healthcare · Biotechnology · NCM

$1.91

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$964M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.52

Based on estimated future earnings — lower means cheaper

Rev Growth

+1,572.1%

Year-over-year revenue change

Profit Margin

-37.5%

How much profit the company keeps from each dollar of revenue

ROE

-16.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.10

+62% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

https://www.lexpharma.com

Country: United States Employees: 81 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.732

Good returns relative to risk taken

Kelly Fraction

-0.0054

No positive edge detected — the data suggests staying out

Calmar Ratio

0.184

Drawdown risk outweighs the returns — higher risk profile

Annual Return

16.2%

Historical annualised return based on price data

Max Drawdown

-87.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.53

25% below the year high

52W Low

$0.62

208% above the year low

Avg Volume

2,671,995

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.07

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.49

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

90.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4.7%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$70M

Total revenue over the last 12 months

Net Income

$-26,089,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$6.00

Target Median

$3.10

Target Low

$1.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go